Rino Rappuoli Selected Research

Vaccines

1/2022	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines.
1/2022	Challenges for Vaccinologists in the First Half of the Twenty-First Century.
1/2022	Immune response in COVID-19: what is next?
12/2021	Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants.
10/2021	Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
4/2021	Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.
1/2021	Vaccinology in the post-COVID-19 era.
1/2021	The role of vaccines in combatting antimicrobial resistance.
11/2020	Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus.
11/2020	Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rino Rappuoli Research Topics

Disease

62	Infections 01/2022 - 01/2002
34	Communicable Diseases (Infectious Diseases) 01/2022 - 05/2003
30	Human Influenza (Influenza) 01/2019 - 12/2005
16	COVID-19 01/2022 - 01/2020
15	Meningococcal Infections 12/2021 - 06/2002
10	Tuberculosis (Tuberculoses) 01/2022 - 11/2006
10	Diphtheria 08/2014 - 02/2003
8	Neoplasms (Cancer) 01/2022 - 05/2011
7	Malaria 01/2022 - 05/2011
6	Bacterial Infections (Bacterial Infection) 01/2021 - 01/2002
6	Whooping Cough (Pertussis) 11/2009 - 07/2003
5	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 11/2005
4	Virus Diseases (Viral Diseases) 04/2021 - 06/2012
4	Emerging Communicable Diseases (Emerging Infectious Diseases) 04/2021 - 10/2009
4	Meningitis 10/2020 - 06/2002
3	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 07/2011
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 08/2014
3	Tetanus 07/2011 - 01/2004
2	Parasitic Diseases (Parasitic Disease) 01/2022 - 01/2016
2	Bacillary Dysentery (Shigellosis) 10/2021 - 09/2021
2	Persistent Infection 01/2021 - 05/2014
2	Narcolepsy 01/2019 - 07/2015
2	Pneumococcal Infections 11/2014 - 07/2011
2	Noncommunicable Diseases 08/2014 - 10/2011
2	Smallpox (Variola) 06/2014 - 05/2010
2	Meningococcal Meningitis 11/2013 - 02/2012
2	Urinary Tract Infections (Urinary Tract Infection) 01/2012 - 03/2010
2	Sepsis (Septicemia) 01/2012 - 06/2002
2	Vaccine-Preventable Diseases 07/2011 - 12/2008
1	Necrosis 01/2021
1	Pharyngitis (Sore Throat) 11/2020
1	Impetigo (Impetigo Contagiosa) 11/2020
1	Hemolysis 11/2020
1	Cytokine Release Syndrome 10/2020
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Typhoid Fever (Typhoid) 01/2020
1	Yellow Fever 01/2019

Drug/Important Bio-Agent (IBA)

118	VaccinesIBA 01/2022 - 01/2002
24	AntigensIBA 04/2021 - 06/2002
20	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2002
15	AntibodiesIBA 12/2021 - 06/2002
12	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2019 - 04/2006
11	Neutralizing AntibodiesIBA 01/2022 - 02/2003
10	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 06/2002
6	Conjugate VaccinesIBA 10/2020 - 12/2005
6	CRM197 (non-toxic variant of diphtheria toxin)IBA 10/2018 - 02/2004
6	GlycoconjugatesIBA 10/2018 - 09/2004
5	Monoclonal AntibodiesIBA 01/2022 - 08/2004
4	Cytotoxins (Cytolysins)IBA 10/2018 - 09/2008
4	Membrane Proteins (Integral Membrane Proteins)IBA 05/2017 - 02/2006
4	CytokinesIBA 11/2015 - 04/2004
4	MF59 oil emulsionIBA 01/2015 - 08/2009
4	Carrier Proteins (Binding Protein)IBA 07/2011 - 04/2008
4	IronIBA 03/2010 - 10/2003
3	Messenger RNA (mRNA)IBA 01/2022 - 11/2015
3	Immunoglobulin G (IgG)IBA 09/2021 - 02/2010
3	aluminum sulfate (alum)IBA 02/2021 - 01/2016
3	Polysaccharides (Glycans)IBA 11/2020 - 04/2008
3	E coli heat-labile enterotoxinIBA 01/2017 - 09/2009
3	EpitopesIBA 01/2016 - 03/2010
3	Viral ProteinsIBA 07/2015 - 08/2004
3	Inactivated VaccinesIBA 01/2015 - 04/2006
3	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2014 - 05/2013
3	Subunit VaccinesIBA 08/2013 - 09/2009
2	COVID-19 VaccinesIBA 01/2022 - 10/2020
2	pandemrixIBA 01/2019 - 07/2015
2	SolutionsIBA 01/2018 - 01/2004
2	Peptides (Polypeptides)IBA 07/2015 - 08/2009
2	Pertussis ToxinIBA 11/2014 - 01/2005
2	Diphtheria Toxoid (Vaccine, Diphtheria)FDA Link 11/2014 - 03/2010
2	Antiviral Agents (Antivirals)IBA 05/2014 - 01/2008
2	Broadly Neutralizing AntibodiesIBA 08/2013 - 06/2011
2	Hemagglutinins (Hemagglutinin)IBA 08/2013 - 06/2011
2	Complement Factor H (Factor H)IBA 07/2011 - 05/2011
2	ToxoidsIBA 07/2011 - 01/2005
2	Glycoproteins (Glycoprotein)IBA 06/2011 - 11/2005
2	Bacterial Proteins (Bacterial Protein)IBA 05/2011 - 12/2002
2	Pertussis VaccineIBA 05/2011 - 01/2005
2	EnzymesIBA 05/2011 - 11/2009
2	Complement System Proteins (Complement)IBA 07/2010 - 12/2003
2	beta-GlucansIBA 03/2010 - 02/2010
2	Meningococcal Vaccines (Meningococcal Vaccine)IBA 03/2010 - 10/2004
2	ChitosanIBA 12/2005 - 02/2004
2	Immunoglobulin A (IgA)IBA 12/2005 - 12/2004
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2022
1	MAD0004J08IBA 01/2022
1	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2022
1	mRNA VaccinesIBA 12/2021
1	Viral AntigensIBA 12/2021
1	4CMenB vaccineIBA 12/2021
1	Staphylococcal Protein A (Protein A)IBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	SARS-CoV-2 spike proteinIBA 01/2021
1	Interleukin-8 (Interleukin 8)IBA 11/2020
1	Combined VaccinesIBA 10/2020
1	MenACWYIBA 10/2020
1	methylallyl trisulfide (MATS)IBA 01/2019

Therapy/Procedure

8	Therapeutics 01/2022 - 06/2002